http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101804285-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2017-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101804285-B1 |
| titleOfInvention | TCTP-derived C-terminus domain inhibiting the binding of TCTP dimer type IgE-dependent histamine releasing factor to its receptor and the use |
| abstract | FIELD OF THE INVENTION The present invention relates to receptor binding domains of an IgE-dependent histamine releasing factor (HRF) and uses thereof, and more particularly to a receptor binding domain of an IgE-dependent histamine releasing factor Domain and H2 domain were confirmed and the C-terminal of HRF was confirmed and confirming that the binding substance to them suppressed the secretory ability of IL-8, the above-mentioned FL, H2 domain and C-terminal were used for asthma, bronchitis , Chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, urticaria, hay fever, conjunctivitis, allergic diseases of anaphylaxis, bronchitis, pneumonia, arthritis. Inflammatory bowel disease, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatitis, pyelonephritis, glomerulonephritis, osteomyelitis, thyroiditis, uveitis, The present invention is useful for the development and prevention of therapeutic agents for inflammatory diseases such as rheumatoid arthritis and HRF-related diseases including malaria, and screening methods for HRF-related diseases. |
| priorityDate | 2014-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 385.